Static and ELF magnetic fields enhance the in vivo anti-tumor efficacy of cis-platin against lewis lung carcinoma, but not of cyclophosphamide against B16 melanotic melanoma

Pharmacological Research

Volumn 48, Issue 1, 2003, Pages 83-90

  Tofani, S ^a   Barone, D ^b   Berardelli, M ^a   Berno, E ^d   Cintorino, M ^c   Foglia, L ^d   Ossola, P ^a   Ronchetto, F ^a   Toso, E ^b   Eandi, M ^d  

^a Ospedale di Ivrea   (Italy)

^b LCG RBM Bioscience   (Italy)

^c UNIVERSITY OF SIENA   (Italy)

^d UNIVERSITY OF TURIN   (Italy)

Author keywords

B16 melanotic melanoma; Cis platin; Cyclophasphamide; Lewis lung carcinoma; Magnetic fields

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; PLATINUM; REACTIVE OXYGEN METABOLITE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DNA BINDING; DRUG EFFICACY; DRUG POTENTIATION; DRUG UPTAKE; EXPERIMENTAL MELANOMA; IMMUNOCOMPETENT CELL; LEWIS CARCINOMA; METASTASIS INHIBITION; MOUSE; NONHUMAN; OXYGEN CONSUMPTION; PRIORITY JOURNAL; SPECIES COMPARISON; SURVIVAL TIME; TUMOR CELL;

EID: 12444271017     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1043-6618(03)00062-8     Document Type: Article

References (22)

1. Cuzick J., Holland R., Barth V., Davies R., Faupel M., Fentiman I.et al. Electropotential measurements as a new diagnostic modality for breast cancer. Lancet. 352:1998;359-363.
2. Marino A.A., Iliev I.G., Schwalke M.A., Gonzales E., Marler K.C., Flanagan C.A. Association between cell membrane potential and breast cancer. Tumour Biol. 15:1994;82-89.
3. Capko D., Zhuravkov A., Davies R.J. Transepithelial depolarization in breast cancer. Breast Cancer Res. Treat. 41:1996;230.
4. Szatrowski T.P., Nathan C.F. Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res. 51:1991;794-798.
5. Tofani S. Physics may help chemistry to improve medicine: a possible mechanism for anticancer activity of static and ELF magnetic fields. Physica Medica. 15:1999;291-294.
6. Grisson C.B. Magnetic field effects in biology: a possible mechanisms with emphasis on radical-pair recombination. Chem. Rev. 95:1995;3-22.
7. Lander M. An essential role for free radicals and derived species in signal transduction. FASEB J. 11:1997;118-124.
8. Polyak K., Xia Y., Zweier J.L., Kinzier K.W., Volgestein B.A. Model for p53-induced apoptosis. Nature. 389:1997;300-305.
9. Sherr C.J. Cancer cell cycles. Science. 274:1996;1672-1677.
10. Tofani S., Barone D., Cintorino M., Ferrara A., Ossola P., Rolfo K.et al. Tumor growth inhibition, apoptosis and loss of p53 expression induced in vitro and in vivo by magnetic fields. Proc. Am. Ass. Cancer Res. 40:1999;488.
11. Tofani S., Barone D., Cintorino M., de Santi M.M., Ferrara A., Orlassino R.et al. Static and ELF magnetic fields induce growth inhibition and apoptosis. Bioelectromagnetics. 22:2001;419-428.
12. Tofani S., Cintorino M., Barone D., Berardelli M., de Santi M.M., Ferrara A.et al. Increased mouse survival, tumor growth inhibition and decreased immunoreactive p53 after exposure to magnetic fields. Bioelectromagnetics. 23:2002;234-242.
13. Tofani S, Barone D, Peano S, Ossola P, Ranchero F, Cintorino M. Anticancer activity by magnetic fields: inhibition of metastatic spread and growth in a breast cancer model. IEEE Trans Plasma Sci 2002;30:1552-7.
14. Geran RI, Greenberg NH, Macdonald MM, Schumacher AM, Abbott BJ. Protocols for screening chemical agents and natural products against animal tumors and other biological systems. 3rd ed. Drug Evaluation Branch, Drug Research and Development National Cancer Institute, National Institutes of Health, Bethesda, MD, USA, 24 May 1972.
15. Tofani S. Electromagnetic field exposure system for the study of possible anti-cancer activity. IEEE Trans. Electromagn. Compat. 44:2002;148-151.
16. Polk C. Dosimetry of extremely-low-frequency magnetic fields. Bioelectromagnetics. 1(Suppl.):1992;209-235.
17. Sabo J., Mirossay L., Horovcak L., Sarissky M., Mirossay A., Mojzis J. Effects of static magnetic field on human leukemic cell line HL-60. Bioelectrochemistry. 56:2002;227-231.
18. Hannan C.J. Jr., Liang Y., Allison J.D., Pantazis C.G., Searle J.R. Chemotherapy of human carcinoma xenografts during pulsed magnetic field exposure. Anticancer Res. 14:1994;1521-1524.
19. Masuda H., Tanaka T., Takahama U. Cisplatin generates superoxide anion by interaction with DNA in a cell-free system. Biochem. Biophys. Res. Commun. 203:1994;1175-1180.
20. Maruyama M., Asano T., Nakagohri T., Uematsu T., Hasegawa M., Miyauchi H.et al. Application of high energy shock waves to cancer treatment in combination with cisplatin and ATX-70. Anticancer Res. 19:1999;1989-1994.
21. Tonetti M., Giovine M., Gasparini A., Benatti U., De Flora A. Enhanced formation of reactive species from cis-diammine-(1,1-cyclobutanedicarboxylato)-platinum(II) (carboplatin) in the presence of oxygen free radicals. Biochem. Pharmacol. 46:1993;1377-1383.
22. Cadossi R., Zucchini P., Emilia G., Franceschi C., Cossarizza A., Santantonio M.et al. Effect of low frequency low energy pulsing electromagnetic fields on mice injected with cyclophosphamide. Exp. Hematol. 19:1991;196-201.